Through the activation of bitter taste receptors, lidocaine has the potential to kill some cancer cells.

Published Date: 27 Nov 2023

Lidocaine activates specific bitter taste receptors via two distinct mechanisms; it is frequently used as a numbing agent for outpatient medical procedures.

Read Full News

Latest News

Nonpharmacologics May Reduce Anxiety, Depression in SUD

Neuromodulation, mind-body therapy, and other nonpharmacologic interventions are linked to improved psychiatric symptoms in people with SUD, a meta-analysis shows.

WHO Warns Loosely Regulated Nicotine Pouches Risk Youth Addiction

The World Health Organization on Friday urged governments to do more to control the sale of nicotine pouches, warning ⁠that the highly addictive products were being...

Non-Factor Therapies in Hemophilia: Cutting-Edge Approaches to Individualize Care

Non-Factor Therapies in Hemophilia: Cutting-Edge Approaches to Individualize Care

Precision Medicine in mHSPC: Integrating Novel Biomarkers, Imaging, and Emerging Targeted Agents

Precision Medicine in mHSPC: Integrating Novel Biomarkers, Imaging, and Emerging Targeted Agents

Accelerating the Evidence-Based Integration of Menin Inhibitors Into R/R AML Care: A Live Expert TheraTalk

Accelerating the Evidence-Based Integration of Menin Inhibitors Into R/R AML Care: A Live Expert TheraTalk

Frontline Decisions in Transplant-Ineligible Multiple Myeloma: Evaluating Quadruplet Therapy

Frontline Decisions in Transplant-Ineligible Multiple Myeloma: Evaluating Quadruplet Therapy

Todays Updates

EMA Backs Breast Cancer SERD After FDA No Vote

The recommendation follows phase 3 data showing longer progression-free survival when patients switched to camizestrant plus a CDK4/6 inhibitor.

Datopotamab Deruxtecan Earns New Breast Cancer Indication

The antibody drug conjugate was approved by the FDA for certain patients with triple-negative breast cancer.

Todays Updates

EMA Backs Breast Cancer SERD After FDA No Vote

The recommendation follows phase 3 data showing longer progression-free survival when patients switched to camizestrant plus a CDK4/6 inhibitor.

Datopotamab Deruxtecan Earns New Breast Cancer Indication

The antibody drug conjugate was approved by the FDA for certain patients with triple-negative breast cancer.

Latest News

Neuromodulation, mind-body therapy, and other nonpharmacologic interventions are linked to improved psychiatric symptoms in people with SUD, a meta-analysis shows.

The World Health Organization on Friday urged governments to do more to control the sale of nicotine pouches, warning ⁠that the highly addictive products were being...

Non-Factor Therapies in Hemophilia: Cutting-Edge Approaches to Individualize Care

Precision Medicine in mHSPC: Integrating Novel Biomarkers, Imaging, and Emerging Targeted Agents

Accelerating the Evidence-Based Integration of Menin Inhibitors Into R/R AML Care: A Live Expert TheraTalk

Frontline Decisions in Transplant-Ineligible Multiple Myeloma: Evaluating Quadruplet Therapy

News All Time

SCOTUS Grapples With Multibillion-Dollar Lawsuits Over Roundup Cancer Claims

Several justices seemed sympathetic to Monsanto's argument that it can't be sued under state law

Rectal Cancer 'Crisis'; Smells Like Cancer; Flushing Away Clues to Colon Cancer

News, features, and commentary about cancer-related issues

Lung Cancer Screening Rates in Eligible Adults Remain Low, Uneven

However, rates were improved from previous survey results

FDA Says First 'Real-Time' Clinical Trial Is Underway

Two sponsors are on board, with a larger pilot program planned later this year

Novel Mimetic Bispecific Antibody Superior to Standard Care in Hemophilia A

Mim8 prophylaxis significantly reduced bleeding events in patients with or without inhibitors

High Rate of Surgical Success in Complex NSCLC With Neoadjuvant Chemoimmunotherapy

Three-fourths of patients had cancer-free mediastinal lymph nodes, clear surgical margins in 93%

Pooled Cord Blood Transplants Achieve Near-Perfect Results in Early Trial

Disease-free survival of 96% with no severe GVHD in acute leukemia, other blood cancers

FDA Panel Endorses Capivasertib Use in Prostate Cancer

Agency staff expressed uncertainty over whether PFS benefit was "clinically meaningful"

Paging Dr. AI; Myth Busting in Cancer; Oncologists Shine in Malpractice Survey

News, features, and commentary about cancer-related issues

J. Craig Venter, Who Won the Race to Sequence the Human Genome, Dies at 79

His death followed a hospitalization for cancer treatment side effects

I Was Told I Had 6 Months to Live. That Was 20 Years Ago.

Here's what two brain surgeries taught me about public health and care access

Woman Loses 6-Year Battle With Mouth Tumor

Rare ameloblastoma rapidly recurs and metastasizes despite numerous radical excisions

Why Did Rare Cancer Shrink on Its Own?

Case illustrates the mystery of spontaneous regression

What Caused a Man to Develop Friable Bleeding Nodules on His Arms and Hips?

The cause lies in a lengthy history of cancer treatment, confirmed by histopathology analysis

Oncologist on Hantavirus Cruise; Bile Duct Cancer Drug OK'd; Untreated Lung Cancers

News, features, and commentary about cancer-related issues

Babies Are Bleeding to Death as Parents Reject a Vitamin Shot Given at Birth

Deaths directly attributed to vitamin K deficiency bleeding have started to climb in recent years

Recommended News For You

Multidrug Regimen Could Change Treatment Landscape for Relapsed/Refractory DLBCL

Innovative oncology therapeutics are being created in collaboration between Moderna and Immatics.

Researchers Challenge USPSTF's Lung Cancer Screening Criteria

Pancreatic Cancer: A Novel CD40 Agonist-Chemo Combo Shows Promise.

For older LBCL patients, Axi-Cel exhibits durable responses and extends overall survival.

A study on lung cancer provides additional proof of the value of screening.

Experts Debate AQUILA Trial Findings in Smoldering Multiple Myeloma

Recommended Articles For You

Harnessing Cuproptosis: A Novel Nanomedicine Strategy for Triple-Negative Breast Cancer 

Neoepitope Vaccines in Oncology: Precision, Sequencing, and Immunotherapy Frontiers 

A Comprehensive Guide to Using an ABG Calculator for Accurate Diagnosis 

Cancer-Keeper Genes: Novel Therapeutic Targets for Disrupting Tumor Maintenance 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Imfinzi + Imjudo, EU approved for patients with advanced lung cancer and non-small cell lung cancer: AstraZeneca

2.

More Support for Early Detection; Cancer in Men Rising; Diet Drives Colon Cancer

3.

Asymptomatic Brain Metastases in EGFR-Mutant NSCLC

4.

Mapping lifelong chronic health risks for childhood cancer survivors

5.

Adding Chemo to Osimertinib Doubles PFS in Advanced NSCLC

1.

Respiratory Ramifications of Systemic Disease: A Comprehensive Review

2.

Revolutionizing Lung Cancer Treatment: Exploring the Benefits of Wedge Resection Surgery

3.

Trends in Incidence, Care, and Surgery for Medullary Thyroid Cancer: A Review

4.

Cancer Care Advances: Metformin, Digital Tools, and Artificial Renal Support

5.

Molecular Mechanisms, Clinical Efficacy, and Stem Cell Therapy Integration in Leukemia Treatment

1.

International Lung Cancer Congress®

2.

Genito-Urinary Oncology Summit 2026

3.

Future NRG Oncology Meeting

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

Treatment Paradigm for Patients with R/R Adult B-cell ALL- Expert Discussions

2.

First Line Combination Therapy- The Overall Survival Data in NSCLC Patients

3.

Guideline Recommendations of Lorlatinib as First-Line Treatment for ALK+ NSCLC

4.

A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part II

5.

Expert Group meeting with the management of EGFR mutation positive NSCLC - Part III

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot